Restricted accessResearch articleFirst published online 2014-01
Postprandial Glycemic Control Conditions in Relation to Urinary N -Acetyl- β - d -Glucosaminidase in Patients with Type 2 Diabetes Mellitus Without Low Glomerular Filtration Rate
This study assessed the relationship between the serum level of 1,5-anhydroglucitol (1,5-AG), a marker of postprandial hyperglycemia, and the ratio of the urinary activity of N-acetyl-β-d-glucosaminidase (NAG) to creatinine (NAG index) in patients with type 2 diabetes mellitus.
Subjects and
Methods: This was a cross-sectional study with 153 patients who had an estimated glomerular filtration rate of ≥60 mL/min/1.73 m2 and no proteinuria and who had never been treated with oral hypoglycemic agents or insulin. On the basis of 1,5-AG levels, the patients were divided into a High 1,5-AG group (>14.0 μg/mL) and a Low 1,5-AG group (≤14.0 μg/mL).
Results:
The logarithmically transformed NAG index was significantly higher in the Low 1,5-AG group than in the High 1,5-AG group when all glycated hemoglobin (HbA1c) levels were included. The logarithmically transformed NAG index was lowest in the High 1,5-AG group with an HbA1c level of ≤6.4% and was highest in the Low 1,5-AG group with an HbA1c level of ≥7.5%. Multivariate regression analysis showed that the NAG index had a higher independent association with 1,5-AG than with HbA1c or the fasting plasma glucose level. In all models, multivariate regression analyses showed that the NAG index was correlated with age.
Conclusions:
These results suggest that postprandial hyperglycemia correlates with early renal tubule injury in type 2 diabetes mellitus.
Get full access to this article
View all access options for this article.
References
1.
The DECODE Study Group on behalf of the European Diabetes Epidemiology Group: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet, 1999; 354:617–621.
2.
TominagaM, IgarashiK, EguchiH, IgarashiK, KatoT, SekikawaA: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care, 1999; 22:920–924.
3.
BonoraE, CalcaterraF, LombardiS, BonfanteN, FormentiniG, BonadonnaRC, MuggeoM: Plasma glucose levels throughout the day and HbA1c interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care, 2001; 24:2023–2029.
4.
American Diabetes Association: Postprandial blood glucose. Diabetes Care, 2001; 24:775–778.
5.
DunganKM, BuseJB, LargayJ, KellyMM, ButtonEA, KatoS, WittlinS: 1,5-Anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care, 2006; 29:1214–1219.
6.
McGillJB, ColeTG, NowatzkeW, HoughtonS, AmmiratiEB, GautilleT, SarnoMJ: Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay. Diabetes Care, 2004; 27:1859–1865.
7.
YamanouchiT, InoueT, OgataE, KashiwabaraA, OgataN, SekinoN, YoshimuraT, IchiyanagiK, KawasakiT: Post-load glucose measurements in oral glucose tolerance tests correlate well with 1,5-anhydroglucitol, an indicator of overall glycaemic state, in subjects with impaired glucose tolerance. Clin Sci (Lond), 2001; 101:227–233.
8.
MatsumotoK, YanoM, MiyakeS, UekiY, YamaguchiY, AkazawaS, TominagaY: Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients. Diabetes Care, 1998; 21:256–260.
9.
VaidyaVS, NiewczasMA, FicocielloLH, JohnsonAC, CollingsFB, WarramJH, KrolewskiAS, BonventreJV: Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-β-d-glucosaminidase. Kidney Int, 2011; 79:464–470.
10.
DammanK, MassonS, HillegeHL, MaggioniAP, VoorsAA, OpasichC, van VeldhuisenDJ, MontagnaL, CosmiF, TognoniG, TavazziL, LatiniR: Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J, 2011; 32:2705–2712.
11.
WhitingPH, NichollsAJ, CattoGRD, EdwardN, EngesetJ: Patterns of N-acetyl-β-d-glucosaminidase excretion after renal transplantation. Clin Chim Acta, 1980; 108:1–7.
12.
DienerU, KnollE, LangerB, RautenstrauchH, RatgeD, WisserH: Urinary excretion of N-acetyl-β-d-glucosaminidase and alanine aminopeptidase in patients receiving amikacin or cis-platinum. Clin Chim Acta, 1981; 112:149–157.
13.
DanceN, PriceRG, CattellWR, LansdellJ, RichardsB: The excretion of N-acetyl-β-glucosaminidase and β-galactosidase by patients with renal disease. Clin Chim Acta, 1970; 27:87–92.
14.
GibeyR, DupondJL, AlberD, Leconte des FlorisR, HenryJC: Predictive value of urinary N-acetyl-beta-d-glucosaminidase (NAG), alanine-aminopeptidase (AAP) and beta-2-microglobin (β2M) in evaluating nephrotoxicity of gentamicin. Clin Chim Acta, 1981; 116:25–34.
15.
KernEF, ErhardP, SunW, GenuthS, WeissMF: Early urinary markers of diabetic kidney disease: a nested case-control study from the Diabetes Control and Complications Trial (DCCT). Am J Kidney Dis, 2010; 55:824–834.
16.
OhkuboY, KishikawaH, ArakiE, MiyataT, IsamiS, MotoyoshiS, KojimaY, FuruyoshiN, ShichiriM: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract, 1995; 28:103–117.
17.
YamanouchiT, KawasakiT, YoshimuraT, InoueT, KoshibuE, OgataN, FunatoH, AkaokaI, MiyashitaH: Relationship between serum 1,5-anhydroglucitol and urinary excretion of N-acetylglucosaminidase and albumin determined at onset of NIDDM with 3-year follow-up. Diabetes Care, 1998; 21:619–624.
18.
KashiwagiA, KasugaM, ArakiE, OkaY, HanafusaT, ItoH, TominagaM, OikawaS, NodaM, KawamuraT, SankeT, NambaM, HashiramotoM, SasaharaT, NishioY, KuwaK, UekiK, TakeiI, UmemotoM, MurakamiM, YamakadoM, YatomiY, OhashiH; Committee on the Standardization of Diabetes Mellitus-Related Laboratory Testing of Japan Diabetes Society: International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetol Int, 2012; 3:8–10.
19.
MatsuoS, ImaiE, HorioM, YasudaY, TomitaK, NittaK, YamagataK, TominoY, YokoyamaH, HishidaA; Collaborators developing the Japanese equation for estimated GFR: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis, 2009; 53:982–992.
20.
YoshiokaK, AzukariK, YoshidaT, KondoM: Rapid improvement of serum 1,5-anhydroglucitol concentrations after administration of α-glucosidase inhibitor. Diabetes Care, 1997; 20:462.
FukumuraY, TajimaS, OshitaniS, UshijimaY, KobayashiI, HaraF, YamamotoS, YabuuchiM: Fully enzymatic method for detecting 1,5-anhydro-d-glucitol in serum. Clin Chem, 1994; 40:2013–2016.
23.
OuchiM, ObaK, YamashitaH, OkazakiM, TsunodaM, OharaM, SekimizuK, WatanabeK, SuzukiT, NakanoH: Effects of sex and age on serum 1,5-anhydroglucitol in nondiabetic subjects. Exp Clin Endocrinol Diabetes, 2012; 120:288–295.
24.
WatanabeM, KokuboY, HigashiyamaA, OnoY, MiyamotoY, OkamuraT: Serum 1,5-anhydro-d-glucitol levels predict first-ever cardiovascular disease: an 11-year population-based cohort study in Japan, the Suita study. Atherosclerosis, 2011; 216:477–483.
25.
MagriCJ, FavaS: The role of tubular injury in diabetic nephropathy. Eur J Intern Med, 2009; 20:551–555.
26.
PhillipsA, JanssenU, FloegeJ: Progression of diabetic nephropathy, insights from cell culture studies and animal models. Kidney Blood Press Res, 1999; 22:81–97.
27.
GilbertRE, CooperME: The tubulointerstitium in progressive diabetic kidney disease: more than aftermath of glomerular injury?. Kidney Int, 1999; 56:1627–1637.
28.
AldermanMH, MelcherL, DrayerDE, ReidenbergMM: Increased excretion of urinary N-acetyl-β-glucosaminidase in essential hypertension and its decline with antihypertensive therapy. N Engl J Med, 1983; 309:1213–1217.
29.
NautaFL, BoertienWE, BakkerSJ, van GoorH, van OeverenW, de JongPE, BiloH, GansevoortRT: Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care, 2011; 34:975–981.
30.
FuWJ, XiongSL, FangYG, WenS, ChenML, DengRT, ZhengL, WangSB, PenLF, WangQ: Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study. Endocrine, 2012; 41:82–88.
31.
OuchiM, SuzukiT, HashimotoM, MotoyamaM, OharaM, SuzukiK, IgariY, WatanabeK, NakanoH, ObaK: Urinary N-acetyl-β-d-glucosaminidase levels are positively correlated with 2-hour plasma glucose levels during oral glucose tolerance testing in prediabetes. J Clin Lab Anal, 2012; 26:473–480.
32.
EllisEN, BrouhardBH, LagroneL, TravisLB: Urinary excretion of N-acetyl-beta-d-glucosaminidase in children with type 1 diabetes mellitus. Diabetes Care, 1983; 6:251–255.
33.
ObaK, HiraiM, AjiroY, OkazakiK, SatoS, SasaiK, SuzukiT, NakanoH, MetoriS: Effect of age on urinary excretion of N-acetyl-β-d-glucosaminidase. J Nippon Med Sch, 1999; 66:33–36.
